These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 21606452)

  • 41. New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonists.
    Pinna A; Wardas J; Simola N; Morelli M
    Life Sci; 2005 Nov; 77(26):3259-67. PubMed ID: 15979104
    [TBL] [Abstract][Full Text] [Related]  

  • 42. L-DOPA-induced dyskinesias, motor fluctuations and health-related quality of life: the COPARK survey.
    Perez-Lloret S; Negre-Pages L; Damier P; Delval A; Derkinderen P; Destée A; Meissner WG; Tison F; Rascol O;
    Eur J Neurol; 2017 Dec; 24(12):1532-1538. PubMed ID: 28940893
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Can adenosine A
    Kanda T; Jenner P
    Parkinsonism Relat Disord; 2020 Nov; 80 Suppl 1():S21-S27. PubMed ID: 33349576
    [TBL] [Abstract][Full Text] [Related]  

  • 44. L-DOPA disrupts adenosine A(2A)-cannabinoid CB(1)-dopamine D(2) receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: biochemical and behavioral studies.
    Pinna A; Bonaventura J; Farré D; Sánchez M; Simola N; Mallol J; Lluís C; Costa G; Baqi Y; Müller CE; Cortés A; McCormick P; Canela EI; Martínez-Pinilla E; Lanciego JL; Casadó V; Armentero MT; Franco R
    Exp Neurol; 2014 Mar; 253():180-91. PubMed ID: 24412491
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.
    Pinna A; Ko WK; Costa G; Tronci E; Fidalgo C; Simola N; Li Q; Tabrizi MA; Bezard E; Carta M; Morelli M
    Mov Disord; 2016 Apr; 31(4):501-11. PubMed ID: 26871939
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD.
    Oliveri RL; Annesi G; Zappia M; Civitelli D; Montesanti R; Branca D; Nicoletti G; Spadafora P; Pasqua AA; Cittadella R; Andreoli V; Gambardella A; Aguglia U; Quattrone A
    Neurology; 1999 Oct; 53(7):1425-30. PubMed ID: 10534246
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson's Disease: A Pooled Analysis of 8 Phase 2b/3 Trials.
    Hauser RA; Hattori N; Fernandez H; Isaacson SH; Mochizuki H; Rascol O; Stocchi F; Li J; Mori A; Nakajima Y; Ristuccia R; LeWitt P
    J Parkinsons Dis; 2021; 11(4):1663-1675. PubMed ID: 34486986
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dyskinetic Parkinson's disease patients demonstrate motor abnormalities off medication.
    Stevenson JK; Talebifard P; Ty E; Oishi MM; McKeown MJ
    Exp Brain Res; 2011 Oct; 214(3):471-9. PubMed ID: 21877102
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neuroimaging of dyskinesia.
    Brooks DJ; Piccini P; Turjanski N; Samuel M
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S154-8; discussion S158-9. PubMed ID: 10762143
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The effects of adenosine A2A receptor antagonists on haloperidol-induced movement disorders in primates.
    Varty GB; Hodgson RA; Pond AJ; Grzelak ME; Parker EM; Hunter JC
    Psychopharmacology (Berl); 2008 Oct; 200(3):393-401. PubMed ID: 18594798
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Serotonergic markers in Parkinson's disease and levodopa-induced dyskinesias.
    Cheshire P; Ayton S; Bertram KL; Ling H; Li A; McLean C; Halliday GM; O'Sullivan SS; Revesz T; Finkelstein DI; Storey E; Williams DR
    Mov Disord; 2015 May; 30(6):796-804. PubMed ID: 25649148
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A double-blind crossover, placebo-controlled study of the adenosine A2A antagonist theophylline in Parkinson's disease.
    Kulisevsky J; Barbanoj M; Gironell A; Antonijoan R; Casas M; Pascual-Sedano B
    Clin Neuropharmacol; 2002; 25(1):25-31. PubMed ID: 11852293
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adenosine A2A antagonists in Parkinson's disease: what's next?
    Hickey P; Stacy M
    Curr Neurol Neurosci Rep; 2012 Aug; 12(4):376-85. PubMed ID: 22585137
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Preclinical Evaluation and Quantification of
    Khanapur S; van Waarde A; Dierckx RA; Elsinga PH; Koole MJ
    J Nucl Med; 2017 Mar; 58(3):466-472. PubMed ID: 27789720
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Behavioral control by striatal adenosine A
    Taura J; Valle-León M; Sahlholm K; Watanabe M; Van Craenenbroeck K; Fernández-Dueñas V; Ferré S; Ciruela F
    Genes Brain Behav; 2018 Apr; 17(4):e12432. PubMed ID: 29053217
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET.
    Tedroff J; Pedersen M; Aquilonius SM; Hartvig P; Jacobsson G; Långström B
    Neurology; 1996 May; 46(5):1430-6. PubMed ID: 8628494
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dysfunctional inhibitory control in Parkinson's disease patients with levodopa-induced dyskinesias.
    Picazio S; Ponzo V; Caltagirone C; Brusa L; Koch G
    J Neurol; 2018 Sep; 265(9):2088-2096. PubMed ID: 29980853
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Changes in glutamate receptors in dyskinetic parkinsonian monkeys after unilateral subthalamotomy.
    Jourdain VA; Morin N; Grégoire L; Morissette M; Di Paolo T
    J Neurosurg; 2015 Dec; 123(6):1383-93. PubMed ID: 25932606
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Interaction of adenosine receptors with other receptors from therapeutic perspective in Parkinson's disease.
    Morin N; Di Paolo T
    Int Rev Neurobiol; 2014; 119():151-67. PubMed ID: 25175965
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rabphilin 3A: A novel target for the treatment of levodopa-induced dyskinesias.
    Stanic J; Mellone M; Napolitano F; Racca C; Zianni E; Minocci D; Ghiglieri V; Thiolat ML; Li Q; Longhi A; De Rosa A; Picconi B; Bezard E; Calabresi P; Di Luca M; Usiello A; Gardoni F
    Neurobiol Dis; 2017 Dec; 108():54-64. PubMed ID: 28823933
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.